Advanced search
Publication Cover
Expert Opinion on Orphan Drugs Volume 9, 2021 - Issue 11-12
Submit an article Journal homepage
230
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies

Kathleen L. MillerOffice of Orphan Products Development, Office of Clinical Policy and Programs, Office of the Commissioner, US Food and Drug AdministrationCorrespondence[email protected]
,
Selma KraftOffice of Orphan Products Development, Office of Clinical Policy and Programs, Office of the Commissioner, US Food and Drug Administration
,
Abraham IpeOffice of Orphan Products Development, Office of Clinical Policy and Programs, Office of the Commissioner, US Food and Drug Administration
&
Lewis FermaglichOffice of Orphan Products Development, Office of Clinical Policy and Programs, Office of the Commissioner, US Food and Drug Administration
Pages 265-272 | Received 24 Oct 2021, Accepted 23 Feb 2022, Published online: 01 Mar 2022

References

  • Orphan Drug Act. P.L. 97–414 (Jan 4, 1983).
  • Patel S, Needleman KIM. FDA’s office of orphan products development: providing incentives to promote the development of products for rare diseases. J Pharmacokinet Pharmacodyn. 2019;46(5):387–393.
  • “Protection for drugs for rare diseases or condition”. (2011). 21 U.S.C. § 360cc(a)(2).
  • “Content and format of a request for orphan-drug designation”. (2021). 21 C.F.R. §316.20.
  • Miller KL, Lanthier M. Trends in orphan new molecular entities, 1983–2014: half were first in class, and rare cancers were the most frequent target. Health Affairs. 2016;35(3):464–470.
  • Miller KL, Lanthier M. Investigating the landscape of US orphan product approvals. Orphanet J Rare Dis. 2018;13(1):183.
  • Kesselheim AS, Wang B, and Franklin JM, et al. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ. 2015;351:h4633.
  • Miller KL, Fermaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021;16(1):1–10.
  • US Food and Drug Administration Center for Drug Evaluation and Research. “Advancing health through innovation: new drug therapy approvals”. 2020 Accessed 8 12 2021. [ Avaliable from: https://www.fda.gov/media/144982/download].
  • Wellman-Labadie O, Zhou Y. The US orphan drug act: rare disease research stimulator or commercial opportunity? Health Policy. 2010;95(2):216–228.
  • Lichtenberg FR, and Waldfogel J. Does misery love company? Evidence from pharmaceutical markets before and after the orphan drug act. Cambridge, MA: National Bureau of Economic Research; 2003.
  • Miller KL. Do investors value the FDA orphan drug designation?. Orphanet J Rare Dis. 2017;12(1):114.
  • Bagley N, Berger B, Chandra A, et al. The orphan drug act at 35: observations and an outlook for the twenty-first century. Innov Policy Econ. 2019;19(1):97–137.
  • Sarpatwari A, Beall RF, Abdurrob A, et al. Evaluating the impact of the orphan drug act’s seven-year market exclusivity period. Health Affairs. 2018;37(5):732–737.
  • Kerr KW, Glos LJ. Effective market exclusivity of new molecular entities for rare and non-rare diseases. Pharm Med. 2020;34(1):19–29.
  • Polamreddy P, Gattu N. The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. Drug Discov Today. 2019;24(3):789–795.
  • Roessler HI, Knoers NV, van Haelst MM, et al. Drug repurposing for rare diseases. Trends Pharmacol Sci. 2021;42(4):255–267.
  • Bloom BE. Recent successes and future predictions on drug repurposing for rare diseases. Expert Opin Orphan Drugs. 2016;4(1):1–4.
  • Allarakhia M. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Devel Ther. 2013;7:753.
  • Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.
  • US Food and Drug Administration. “Search orphan drug designations and approvals”. [ Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/]. Accessed Jan 2021.
  • World Health Organization WH. “ATC Classification”. [ Available from: https://www.who.int/tools/atc-ddd-toolkit/atc-classification]. Accessed May 2021.
  • Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, et al. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20(8):1027–1034.
  • Strittmatter SM. Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks. Nat Med. 2014;20(6):590–591.
  • Janciauskiene SM, Nita IM, Stevens T. α1-Antitrypsin, old dog, new tricks: α1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem. 2007;282(12):8573–8582.
  • Tawara I, Sun Y, Lewis EC, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Nat Acad Sci. 2012;109(2):564–569.
  • Corroon J, Kight R. Regulatory status of cannabidiol in the United States: a perspective. Cannabis Cannabinoid Res. 2018;3(1):190–194.
  • US Food and Drug Administration. “EPIDIOLEX® (cannabidiol) oral solution drug label”. 2018. [ Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf]. Accessed May 2021.
  • Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833.
  • Verbaanderd C, Rooman I, Meheus L, et al. Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients. Front Pharmacol. 2020;10:1664.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.